Remind patients that supplements can have adverse effects

Share this content:

Persons with cancer who use herbs or dietary supplements are at risk for harmful drug interactions, a new study has reiterated.

As noted in the International Journal of Clinical Practice report (2012;66[11]:1056-1078), the use of herbs and dietary supplements (HDS) alone or with medications can potentially increase the risk of adverse events experienced by patients with cancer or other diseases. To evaluate documented HDS/drug interactions and contraindications, the investigators conducted a structured literature review that covered a total of 1,491 unique pairs of HDS/drug interactions involving 213 HDS entities and 509 medications.

Overall, HDS/drug interactions and contraindications primarily concerned a relatively small subset of commonly used medications and HDS entities, but the review results may help clinicians identify patients, medications, and HDS products most susceptible to these interactions and contraindications. This, in turn, can help prevent serious adverse events and improve desired therapeutic outcomes for patients with cancer and other diseases.

The analysis of data showed that herbal and botanical remedies were more likely to have documented drug interactions and contraindications than were other dietary supplements studied, such as vitamins, minerals, and amino acids. HDS products containing St. John's wort, magnesium, calcium, iron, and ginkgo had the greatest number of documented interactions with medications.

Drugs affecting the central nervous system or the cardiovascular system had more documented interactions with HDS. The agents warfarin, insulin, aspirin, digoxin, and ticlopidine had the greatest number of reported interactions with HDS. Nearly half (42.3%) of the 882 HDS/drug interactions described occurred due to altered pharmacokinetics. Just over one-fourth (240) were categorized as major interactions.

Flaxseed, echinacea, and yohimbe had the largest number of documented HDS contraindications.Of the 152 identified HDS contraindications, the most frequent involved gastrointestinal (16.4%), neurologic (14.5%), and renal/genitourinary diseases (12.5%).

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs